Large CapHealthcare

BIIB — Biogen Inc.

Biotechnology · Founded 1978 · Cambridge, Massachusetts · CEO: Christopher Viehbacher

Biogen is a biotechnology company specializing in neuroscience, with a legacy portfolio in multiple sclerosis (MS) and expanding into Alzheimer's disease, ALS, and neuropsychiatric disorders. The company's multiple sclerosis drugs (Tecfidera, Tysabri, Avonex, Vumerity) built its revenue base. Biogen attracted significant controversy and attention with Aduhelm and then Leqembi (lecanemab), its Alzheimer's treatments developed in partnership with Eisai. Leqembi received full FDA approval in 2023 and represents Biogen's most significant near-term growth opportunity.

How Biogen Inc. Makes Money

Multiple sclerosis drug portfolio (Tecfidera, Tysabri, Avonex, Vumerity) provides legacy recurring revenue

Leqembi (lecanemab) Alzheimer's treatment royalty-sharing and direct revenue from Eisai co-commercialization

Spinraza (nusinersen) SMA treatment revenue from global sales

Biosimilar revenues from anti-TNF and ophthalmology biosimilars

Key Metrics Investors Watch

Leqembi patient uptake and infusion center adoption rates
MS franchise revenue trajectory vs. generic/biosimilar erosion
Spinraza patient retention vs. gene therapy competitor SMA treatments
Pipeline advancement in Alzheimer's prevention (before symptoms stage)
R&D pipeline cost management and cash runway

Competitive Advantages

Leqembi is one of the first disease-modifying Alzheimer's treatments with full FDA approval
Deep neurological disease expertise built over decades is rare and difficult to replicate
Tysabri remains a preferred MS treatment with high efficacy and patient persistence
Strong patent portfolio and proprietary antibody development capabilities

Key Risks

Leqembi adoption is slower than expected due to complex IV infusion requirements and safety monitoring
MS portfolio faces accelerating biosimilar and generic competition (Tecfidera generics launched)
Alzheimer's market penetration depends on physician and payer acceptance of amyloid-clearing approach
R&D pipeline concentration in neuroscience limits diversification vs. broader pharma peers

Dividend & Capital Return

Biogen does not pay a dividend, preferring to reinvest in R&D and pipeline development for its neurological disease programs.

I Document Every Trade — Even the Losses

Options record: 1W-8L. Net worth: 100% GSE preferred. Get the unfiltered updates.

Unsubscribe anytime. I respect your inbox more than Congress respects property rights.

Frequently Asked Questions

What is Leqembi and why is it significant?

Leqembi (lecanemab), developed with Eisai, is one of the first FDA-approved drugs to demonstrably slow cognitive decline in early Alzheimer's disease by clearing amyloid plaques from the brain. Its approval was considered a major milestone in the decades-long effort to develop Alzheimer's treatments. This is educational content, not financial advice.

What happened with Biogen's Aduhelm?

Aduhelm (aducanumab) was Biogen's first Alzheimer's treatment, approved via the FDA's accelerated approval pathway in 2021. Its approval was highly controversial among scientists, CMS initially restricted Medicare coverage, and Biogen ultimately stopped commercializing it when Leqembi became available. This is educational content, not financial advice.

Does Biogen pay a dividend?

No, Biogen does not currently pay a dividend. The company reinvests cash in its neuroscience pipeline, particularly Alzheimer's research and development. This is educational content, not financial advice.

What multiple sclerosis drugs does Biogen sell?

Biogen's key MS products include Tysabri (natalizumab), Avonex (interferon beta-1a), Plegridy, Vumerity (diroximel fumarate), and Zinbryta. Tecfidera (dimethyl fumarate) was a major product but has faced generic competition. This is educational content, not financial advice.

What is Spinraza?

Spinraza (nusinersen) is Biogen's FDA-approved treatment for spinal muscular atrophy (SMA), a rare genetic neuromuscular disease. It was the first approved therapy for SMA and changed the treatment landscape, though it now faces competition from Novartis's Zolgensma gene therapy. This is educational content, not financial advice.

Related Stocks

ABBV

AbbVie Inc.

Healthcare

AbbVie is a global biopharmaceutical company focused on immunology, oncology, neuroscience, and eye care. Spun off from Abbott Laboratories in 2013, AbbVie is best known for Humira (the world's best-selling drug of all time) and its successor drugs Skyrizi and Rinvoq.

AMGN

Amgen Inc.

Healthcare

Amgen is one of the world's largest biotechnology companies, pioneering the use of recombinant DNA technology to develop medicines for serious illnesses. Its portfolio spans oncology (Blincyto, Lumakras), cardiovascular (Repatha), bone health (Prolia, XGEVA), and inflammatory diseases (Otezla, Enbrel). Amgen has been expanding into biosimilars and acquired Horizon Therapeutics in 2023 to add rare disease therapies. The company generates among the highest profit margins in the pharmaceutical industry.

GILD

Gilead Sciences, Inc.

Healthcare

Gilead Sciences is a biopharmaceutical company specializing in antiviral drugs, particularly for HIV, hepatitis, and COVID-19. Its HIV franchise (Biktarvy, Descovy, Genvoya, Truvada) dominates the global HIV treatment market and generates billions in annual revenue. Gilead's hepatitis C drugs (Harvoni, Sovaldi) effectively cured the disease and transformed the treatment paradigm, though that market has since contracted as the curable population has been treated. Gilead is expanding into oncology through its Kite Pharma (CAR-T cell therapy) platform.

MRNA

Moderna, Inc.

Healthcare

Moderna is a biotechnology company that pioneered messenger RNA (mRNA) therapeutics and vaccines. Its COVID-19 vaccine (Spikevax) was authorized in December 2020 and became one of the best-selling pharmaceutical products in history. Post-pandemic, Moderna is deploying its mRNA platform to develop vaccines for respiratory viruses (RSV, flu-COVID combination), personalized cancer vaccines (with Merck), and rare diseases. The company is in a critical transition from COVID dependence to a diversified pipeline.

Recommended Resources

Tools & books I actually use and recommend

Interactive Brokers

Low commissions, global market access, and professional-grade tools. This is where I hold my positions.

Open an Account

A Random Walk Down Wall Street

Burton Malkiel's classic case for index investing. The book that convinced millions to stop stock-picking.

View on Amazon

TradingView

Best charting platform out there. Real-time data, screeners, and a community of millions of traders.

Try TradingView

Some links above are affiliate links. I only recommend products I personally use. See my full disclosures.

Keep Exploring

Hub

All Stocks

Browse all 134 stock profiles by sector.

Best Stocks For Beginners

Curated stock picks for new investors by goal.

Financial Glossary

Understand the terms investors use every day.

Stock vs ETF

Individual stocks vs ETFs — which is right for you?

ETF Profiles

Deep dives on 90+ ETFs across every category.

Buying Your First Stock

How to open a brokerage and buy your first share.

Browse All 134 Stock Profiles

Company information is based on publicly available disclosures and widely-known business facts. No specific price, earnings, or real-time market data is included. This is educational content — not investment advice.